FY2024 EPS Estimates for CEL-SCI Co. Cut by Zacks Small Cap (NYSE:CVM)

CEL-SCI Co. (NYSE:CVM - Free Report) - Equities researchers at Zacks Small Cap dropped their FY2024 earnings per share (EPS) estimates for shares of CEL-SCI in a research report issued to clients and investors on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten now expects that the company will earn ($0.51) per share for the year, down from their prior forecast of ($0.48). The consensus estimate for CEL-SCI's current full-year earnings is ($0.48) per share.

CEL-SCI (NYSE:CVM - Get Free Report) last announced its earnings results on Wednesday, February 14th. The company reported ($0.14) earnings per share (EPS) for the quarter.

Separately, StockNews.com lowered CEL-SCI from a "hold" rating to a "sell" rating in a research report on Friday, March 15th.

CEL-SCI Stock Down 1.3 %

Shares of NYSE:CVM traded down $0.02 during trading on Wednesday, hitting $1.50. The stock had a trading volume of 133,503 shares, compared to its average volume of 303,426. CEL-SCI has a 12 month low of $1.04 and a 12 month high of $3.23. The company has a market capitalization of $80.97 million, a PE ratio of -2.21 and a beta of 1.29. The firm's fifty day moving average is $2.03 and its 200 day moving average is $2.18. The company has a quick ratio of 0.78, a current ratio of 1.26 and a debt-to-equity ratio of 0.75.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CVM. BNP Paribas Arbitrage SA increased its position in CEL-SCI by 195.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 8,280 shares of the company's stock valued at $37,000 after buying an additional 5,474 shares in the last quarter. FMR LLC boosted its stake in shares of CEL-SCI by 1,061.5% in the 2nd quarter. FMR LLC now owns 9,385 shares of the company's stock worth $42,000 after buying an additional 8,577 shares during the last quarter. MML Investors Services LLC purchased a new position in shares of CEL-SCI in the 3rd quarter worth $31,000. Two Sigma Investments LP purchased a new position in shares of CEL-SCI in the 4th quarter worth $26,000. Finally, XTX Topco Ltd purchased a new position in shares of CEL-SCI in the 1st quarter worth $57,000. Institutional investors own 12.08% of the company's stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.